From heart failure and kidney dysfunction to cardiorenal syndrome: TMAO may be a bridge
The study of trimethylamine oxide (TMAO), a metabolite of gut microbiota, and heart failure and chronic kidney disease has made preliminary achievements and been summarized by many researchers, but its research in the field of cardiorenal syndrome is just beginning. TMAO is derived from the trimethy...
Main Authors: | Jialun Zhang, Peining Zhu, Siyu Li, Yufei Gao, Yue Xing |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-11-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1291922/full |
Similar Items
-
Attenuation of Circulating Trimethylamine N-Oxide Prevents the Progression of Cardiac and Renal Dysfunction in a Rat Model of Chronic Cardiorenal Syndrome
by: Deling Zou, et al.
Published: (2021-10-01) -
Fecal Microbiome Composition Does Not Predict Diet‐Induced TMAO Production in Healthy Adults
by: Marc Ferrell, et al.
Published: (2021-11-01) -
TMAO, a seafood-derived molecule, produces diuresis and reduces mortality in heart failure rats
by: Marta Gawrys-Kopczynska, et al.
Published: (2020-06-01) -
Trimethylamine, a gut bacteria metabolite and air pollutant, increases blood pressure and markers of kidney damage including proteinuria and KIM-1 in rats
by: Klaudia M. Maksymiuk, et al.
Published: (2022-10-01) -
Trimethylamine N-Oxide (TMAO) Plasma Levels in Patients with Different Stages of Chronic Kidney Disease
by: Marcia Ribeiro, et al.
Published: (2024-12-01)